The CDTI SICC Innvierte of investing in Innovation Integrates Pharmaceuticals, along with three coinversores, to develop a platform of gene edition for the treatment of oncology diseases, immune and of genetic origin

Integrates Pharmaceuticals is a company that is creating tools genetic writing next-generation to increase the efficiency and security of advanced therapies.

This company spin off the Universitat Pompeu Fabra (UPF) founded by doctors Marc Güell and Avencia Sánchez-mejías by 2020, has designed the beijing platform for writing FiCAT to develop genetic therapies for cellular immune diseases and, as well as oncological génicas therapies for rare diseases.

In addition, thanks to this technological solution Integrates Pharmaceuticals, is generating data FiCAT proof of concept on its first gene therapy, using systemic administration with viral delivery through nanoparticles lipídicas (LNP) to treat a serious paediatric liver disease.

The CDTI Innovation, through Innvierte, has closed an operation of investment in this endeavour with INVIVO VENTURES, RCF, COLUMBUS LIFE SCIENCES FUND III, F.C.R. and AdBio Partners AFB FUND II, with an amount of investment of $2.7 million euros. This participation, the CDTI Innovation contributes to the launching of new advanced therapies to treat diseases, immune and oncology genetic in origin.

INVIVO VENTURES, RCF

Fondo gestionado por INVIVO PARTNERS, S.G.E.I.C, S.A., firma de capital riesgo especializada en empresas de salud en etapas tempranas.

His team combines scientific, technical and financial shock for investment and foster the growth in the health sector, especially in biotechnology companies that develop innovative medicines, with a particular interest in advanced therapies and synthetic biology.

COLUMBUS VENTURE PARTNERS,

Columbus Venture Partners is a specialized risk capital in biotechnology and health sciences, founded in 2016 (Valencia) by Javier García Cogorro and Damià Tormo. With a model of differential treatment and an investment consolidated record with regard to promoting industrial platforms of advanced therapies, Columbus Venture Partners, actively participates in the creation and growth of more than 80 per cent of their portfolio companies. Nowadays it manages eur 400 million through 4 funds which have resulted in and/or participated 50 companies of the healthcare sector.

AdBio Partners AFB FUND II

The fund managed by AdBio partners, a european firm of venture capital with headquarters in paris and offices in Barcelona, which invests in highly innovative projects. Its strategy combines an extensive experience in the creation of new businesses as well as investments in the initial phase, providing a solid support to boost the growth of the company. Created by 2016, Partners has been AdBio 28 european investments from two seed funds. These companies have attracted more than a billion euros of additional capital from unions and strategic international funds.

Innvierte

Innvierte is an initiative aimed at promoting the entrepreneurial innovation through support to the risk capital investment in technology-based enterprises or innovative programme. This is done through the collective investment type closed Innvierte Sustainable Economy SICC S.M.E., S.A., self-managed and under the supervision of the national Values and that the CDTI Innovation is a shareholder Only.

To date, the CDTI innovation has committed 2,661 M €in 61 investment vehicles that have invested in more than 622 companies, and through its joint investment line directly committed an amount of 723 M €in 190 firms.

Innvierte fits into the strategy for science, technology and innovation 2021-2027, adopted by decision of the council of ministers, in september. This 2020 Strategy contains goals, the reforms and measures to be taken throughout the area of r + D + i in order to boost their growth and impact, and is one of the pillars on which the design of the government's policy in r + D + i for the coming years.

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is the agency for innovation of the ministry of science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.

Further information,

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

Integrates Pharmaceuticals:
Website:https :// integra-tx.com/
In LinkedIn:https :// www.linkedin.com/company/integra-therapeutics/

INVIVO PARTNERS, S.G.E.I.C, S.A:
Website:https :// invivo.partners/
In LinkedIn:https :// www.linkedin.com/company/invivopartners/
X:https :// x.com/InvivoPartners

COLUMBUS VENTURE PARTNERS:
Website:https :// columbusvp.com/
In LinkedIn:https :// www.linkedin.com/company/columbus-venture-partners/

AdBio partners:
Website:http://www.adbio.partners/
In LinkedIn:https :// www.linkedin.com/company/adbiopartners/
X:https :// x.com/AdBiopartners